Investigational drugs for the treatment of olfactory dysfunction

References

• Temmel AF, Quint C, Schickinger-Fischer B, et al. Characteristics of olfactory disorders in relation to major causes of olfactory loss. Arch Otolaryngol Head Neck Surg. 2002;128:635–641. DOI:10.1001/archotol.128.6.635
   PubMedGoogle Scholar
• Schäfer L, Schriever VA, Croy I. Human olfactory dysfunction: causes and consequences. Cell Tissue Res. 2021;383:569–579.
   PubMed Web of Science ®Google Scholar
• Rombaux P, Potier H, Markessis E, et al. Olfactory bulb volume and depth of olfactory sulcus in patients with idiopathic olfactory loss. Eur Arch Otorhinolaryngol. 2010;267:1551–1556.
   PubMed Web of Science ®Google Scholar
• Carnemolla SE, Hsieh JW, Sipione R, et al. Olfactory dysfunction in frontotemporal dementia and psychiatric disorders: a systematic review. Neurosci Biobehav Rev. 2020;118:588–611.
   PubMed Web of Science ®Google Scholar
• D’Ascanio L, Vitelli F, Cingolani C, et al. Randomized clinical trial “olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin”: preliminary results. Eur Rev Med Pharmacol Sci. 2021;25:4156–4162.
   PubMed Web of Science ®Google Scholar
• Di Stadio A, D’Ascanio L, La Mantia I, et al. Parosmia after COVID-19: olfactory training, neuroinflammation and distortions of smell. Eur Rev Med Pharmacol Sci. 2022;26:1–3.
   PubMed Web of Science ®Google Scholar
• Di Stadio A, Costantini C, Renga G, et al. The microbiota/host immune system interaction in the nose to protect from COVID-19. Life (Basel). 2020;10:345.
   Web of Science ®Google Scholar
• Chen CR, Kachramanoglou C, Li D, et al. Anatomy and cellular constituents of the human olfactory mucosa: a review. J Neurol Surg B Skull Base. 2014;75:293–300.
   PubMed Web of Science ®Google Scholar
• Choi R, Goldstein BJ. Olfactory epithelium: cells, clinical disorders, and insights from an adult stem cell niche. Laryngoscope Investig Otolaryngol. 2018;3:35–42.
   PubMed Web of Science ®Google Scholar
• Hummel T, Whitcroft KL, Rueter G, et al. Intranasal vitamin A is beneficial in post-infectious olfactory loss. Eur Arch Otorhinolaryngol. 2017;274:2819–2825.
   PubMed Web of Science ®Google Scholar
• Nguyen TP, Patel ZM. Budesonide irrigation with olfactory training improves outcomes compared with olfactory training alone in patients with olfactory loss. Int Forum Allergy Rhinol. 2018;8:977–981.
   PubMed Web of Science ®Google Scholar
• Varricchio A, La Mantia I, Brunese FP, et al. Smell recovery in patients with COVID-19: an experience with nebulized nasal treatment. J Biol Regul Homeost Agents. 2021;35:683–686.
   PubMed Web of Science ®Google Scholar
• Reden J, Lill K, Zahnert T, et al. Olfactory function in patients with postinfectious and posttraumatic smell disorders before and after treatment with vitamin A: a double-blind, placebo-controlled, randomized clinical trial. Laryngoscope. 2012;122:1906–1909.
   PubMed Web of Science ®Google Scholar
• Mary Beth GenterKrishan M. Rui Daniel Prediger the olfactory system as a route of delivery for agents to the brain and circulation (Chapter 19). In: Doti RL, editor. Handbook of olfaction and gustation. John Wiley & Sons, Inc; 2015. p. 453–484.
   Google Scholar
• Tashima T. Shortcut approaches to substance delivery into the brain based on intranasal administration using nanodelivery strategies for insulin. Molecules. 2020;25(21):5188. Published 2020 Nov 7.
   Web of Science ®Google Scholar
• Dong X. Current strategies for brain drug delivery. Theranostics. 2018 Feb 5;8(6):1481–1493.
   PubMed Web of Science ®Google Scholar
• Crowe TP, Greenlee MHW, Kanthasamy AG, et al. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 2018 Feb 15;195:44–52.
   PubMed Web of Science ®Google Scholar
• Kashyap K, Shukla R. Drug delivery and targeting to the brain through nasal route: mechanisms, applications and challenges. Curr Drug Deliv. 2019;16(10):887–901.
   PubMed Web of Science ®Google Scholar
• Xydakis MS, Albers MW, Holbrook EH, et al. Post-viral effects of COVID-19 in the olfactory system and their implications. Lancet Neurol. 2021;20:753–761.
   PubMed Web of Science ®Google Scholar
• Di Stadio A, Bernitsas E, Ralli M, et al. OAS1 gene, spike protein variants and persistent COVID-19-related anosmia: may the olfactory dysfunction be a harbinger of future neurodegenerative disease? Eur Rev Med Pharm Sci. 2022;2(26): 347–349. DOI:10.26355/eurrev_202201_27858. in press.
   Google Scholar
• Di Stadio A, Brenner MJ, De Luca P, et al. Olfactory dysfunction, headache, and mental clouding in adults with long-COVID-19: what is the link between cognition and olfaction? A cross-sectional study. Brain Sci. 2022;12:x.
   Web of Science ®Google Scholar
• Khan M, Yoo S-J, Clijsters M, et al. Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. Cell. 2021;184:5932–5949.e15.
   PubMed Web of Science ®Google Scholar
• Amruta N, Chastain WH, Paz M, et al. SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders. Cytokine Growth Factor Rev. 2021;58:1–15.
   PubMed Web of Science ®Google Scholar
• Magusali N, Graham AC, Piers TM, et al. A genetic link between risk for Alzheimer’s disease and severe COVID-19 outcomes via the OAS1 gene. Brain. 2021;144:3727–3741.
   PubMed Web of Science ®Google Scholar
• Thiel A, Radlinska BA, Paquette C, et al. The temporal dynamics of poststroke neuroinflammation: a longitudinal diffusion tensor imaging-guided PET study with 11C-PK11195 in acute subcortical stroke. J Nucl Med. 2010;51:1404–1412.
   PubMed Web of Science ®Google Scholar
• Goldberg E, Podell K, Sodickson DK, et al. The brain after COVID-19: compensatory neurogenesis or persistent neuroinflammation? EClinicalMedicine. 2020;31:100684.
   PubMedGoogle Scholar
• Song WJ, Hui CKM, Hull JH, et al. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir Med. 2021 May;9(5):533–544. Kempuraj D, Selvakumar GP, Ahmed ME, Raikwar SP, Thangavel R, Khan A, Zaheer SA, Iyer SS, Burton C, James D, Zaheer A. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation. Neuroscientist. 2020;26: 402-414.
   PubMed Web of Science ®Google Scholar
• Le Bon SD, Konopnicki D, Pisarski N, et al. Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell. Eur Arch Otorhinolaryngol. 2021;278:3113–3117.
   PubMed Web of Science ®Google Scholar
• Schriever VA, Merkonidis C, Gupta N, et al. Treatment of smell loss with systemic methylprednisolone. Rhinology. 2012 Sep;50(3):284–289.
   PubMed Web of Science ®Google Scholar
• Gundamraj S, Hasbun R. The use of adjunctive steroids in central nervous infections. Front Cell Infect Microbiol. 2020 Nov 23;10:592017.
   PubMed Web of Science ®Google Scholar
• Hox V, Lourijsen E, Jordens A, et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy. 2020;10:1.
   PubMed Web of Science ®Google Scholar
• Fernandes AM, Valera FC, Anselmo‐Lima WT. Mechanism of action of glucocorticoids in nasal polyposis. Braz J Otorhinolaryngol. 2008;74(2):279–283.
   PubMedGoogle Scholar
• Lattanzi S, Cagnetti C, Danni M, et al. Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis. J Neurol. 2017 Aug;264(8):1697–1704.
   PubMed Web of Science ®Google Scholar
• Dwyer DF, Ordovas-Montanes J, Allon SJ, et al. Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation. Sci Immunol. 2021 Feb 26;6(56):eabb7221.
   PubMed Web of Science ®Google Scholar
• Di Stadio A, D’Ascanio L, Vaira LA, et al. Ultramicronized Palmitoylethanolamide and Luteolin supplement combined with olfactory training to treat post-COVID-19 olfactory impairment: a multi-center double-blinded randomized placebo-controlled clinical trial. Curr Neuropharmacol. 2022 Apr 20;20:2001–2012.
   Google Scholar
• Gelardi M, Giancaspro R, Cassano M. Should the role of mast cells in chronic rhinosinusitis with nasal polyps be reevaluated? Acta Otorhinolaryngol Ital. 2021 Dec;41(6):576–577.
   PubMed Web of Science ®Google Scholar
• Liu G, Zong G, Doty RL, et al. Prevalence and risk factors of taste and smell impairment in a nationwide representative sample of the US population: a cross-sectional study. BMJ Open. 2016 Nov 9;6(11):e013246.
   PubMed Web of Science ®Google Scholar
• Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
   Google Scholar
• Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative diseases (Review). Mol Med Rep. 2016;13:3391–3396.
   PubMed Web of Science ®Google Scholar
• Grigoriadis N, Grigoriadis S, Polyzoidou E, et al. Neuroinflammation in multiple sclerosis: evidence for autoimmune dysregulation, not simple autoimmune reaction. Clin Neurol Neurosurg. 2006;108:241–244.
   PubMed Web of Science ®Google Scholar
• Bjelobaba I, Savic D, Lavrnja I. Multiple sclerosis and neuroinflammation: the overview of current and prospective therapies. Curr Pharm Des. 2017;23:693–730.
   PubMed Web of Science ®Google Scholar